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Essentials
• Data on surgery in factor XIII (FXIII) deficiency patients are scarce and lack standardized guidelines.
• Variable dosage of 10-50 U kg À1 was given to FXIII deficiency patients undergoing surgery.
• Surgical outcomes showed excellent hemostasis with a minimal risk of post-operative complications.
• Surgery can be performed safely in FXIII deficiency patients following FXIII administration.
Summary. Background: The lack of accepted standardized surgical guidelines leads to dependence on the treating physicians' and centers' experiences. Aim: Our aim is to evaluate the surgical outcomes of a large group of congenital factor XIII deficiency (FXIIID) patients. Methods: A case series study was conducted prior to surgery on congenital FXIIID patients in two major referral centers located in Iran from 2010 to 2016. All patients were on prophylaxis using plasma factor XIII concentrate (10 U kg
À1
, every 28 days) except for three patients. Single doses of 10 U kg À1 or 30 U kg À1 plasma factor XIII concentrate were given before a minor procedure and circumcision, respectively. Two doses of plasma factor XIII concentrate, one 30 U kg À1 prior to the procedure and the second dose of 30 U kg À1 on postoperative day 3, were given for major surgery. The dose was 50 U kg À1 both before and after neurosurgical procedures. Results: One hundred and sixty-two FXIIID patients underwent minor, major and obstetrical/gynecological surgeries. Median age of the patients was 14 years (ages ranged
Introduction
Factor XIII deficiency (FXIIID) is a rare bleeding disorder inherited as an autosomal recessive disorder [1, 2] . The incidence of FXIII deficiency is estimated to be 1-3 per million people, but it is not rare in areas where consanguineous marriage is popular, such as Iran, so that one-third of global FXIIID patients are located in this country [2] [3] [4] [5] . The diagnosis of FXIII deficiency is based upon patient and family history, clinical symptoms and laboratory confirmation [1, [6] [7] [8] .
Umbilical cord bleeding and delayed detachment of the umbilical cord can be seen in at least 80% of patients with FXIII deficiency [1, 9, 10] . Other types of bleeding symptoms can occur in these patients, such as ecchymosis, intramuscular and subcutaneous hematoma, oral cavity bleeding, prolonged bleeding after trauma [2] and intracranial bleeding (30%) [5] . Prophylactic treatment in severe cases makes it possible for patients to lead a normal life; therefore, surgical procedures such as cardiovascular or spinal surgeries are expected to be performed for these patients. Surgery can be performed as an elective or emergency procedure. Trauma-related bleeding in different organs may cause morbidity and mortality during surgical procedures, so that adequate replacement therapy and hemostatic coverage is crucial before and during an operative procedure for patients with bleeding disorders. FXIII has the longest half-life among coagulation factors, leading to easier hemostatic coverage during and after surgical procedures. The hallmark of FXIIID patients undergoing surgery is delayed bleeding. Activated FXIII acts at the final step of the coagulation cascade as a stabilizing factor, causing postoperative delayed bleeding in untreated deficient patients.
Measurements of the activity levels and checking FXIII inhibitors are mandatory prior to surgical procedures. However, clot solubility tests (CST) may be the only available method for evaluating FXIIID in many laboratories and this test seems to be the only way to monitor patients when faced with an emergency or inevitable surgery in such areas. Nevertheless, quantitative factor activity assays should replace CST as much as possible in order to allow precise and close monitoring during surgery. Moreover, CST is not standardized, is no longer recommended and can only identify severe cases, so it might only be possible to monitor postoperative severe FXIIID patients with it. Therefore, CST cannot reliably monitor mild to moderate FXIIID during surgery, which may be accompanied by postoperative bleeding because of low levels of FXIII, indicating the importance of quantitative assays [11, 12] . Non-severe FXIII deficiency patients are usually non-symptomatic and may be diagnosed or bleed after hemostatic stress situations or invasive procedures, confirming that all types of factor XIIID require replacement therapy during surgery [13, 14] .
Data on surgical outcomes in FXIIID patients are scarce. Thus, the goal of this study is to address this gap by providing a survey of the surgical outcomes, including hemostatic and non-hemostatic complications, among a large group of severe congenital FXIIID patients undergoing minor and major surgery and receiving a plasmaderived FXIII concentrate.
Methods

Patients
This is a case series study of congenital FXIIID patients conducted in two major referral centers for coagulation disorders located in southern and southeastern Iran from 2010 to 2016.
All FXIIID patients of all ages with different plasma factor activity levels or a positive CST undergoing surgery were included in this study. All demographic data, types of treatment and surgery and all postoperative complications were recorded. The patients with other types of coagulation disorders, acquired FXIIID or combined FXIIID with other types of coagulation disorders were excluded from the study. Written consent was obtained from patients or their legal guardians before starting the study. Medical ethics committees of both centers approved the study. Three patients who had concomitant diseases with FVII, FX deficiency and beta thalassemia major, were excluded from the study. Finally, a total of 162 patients who underwent major and minor surgeries were included. All patients received a plasmaderived FXIII concentrate (Fibrogammin P, CSL Behring, Marburg, Germany) for surgical procedures.
Laboratory assays
Diagnosis of FXIII deficiency was initially performed by detecting normal prothrombin time and activated partial thromboplastin time, platelet counts and fibrinogen level. A definitive diagnosis was confirmed by qualitative and quantitative methods as well as genetic analysis. Two qualitative tests (monchloroacetic [MCA] acid and 5 molar urea test) and one ammonia release quantitative test (Berichrom Kit, Stago, Marburg, Germany; four channels) were used. Factor activity measurement was not available for 11 patients, who only had a qualitative test. Inhibitor and viral markers were checked prior to surgery. Furthermore, viral markers were also checked at postoperative months 3 and 6 for safety evaluation.
Surgical treatment protocol
All the patients had been on regular prophylaxis, 10 U kg À1 every 28 days, except three, of whom one refused and two were undiagnosed prior to surgery. Because all the surgeries were elective, the date of surgery was scheduled 1-2 days prior to establishing the prophylaxis plan. The patients received one single dose of 10 U kg À1 before a minor procedure and 30 U kg À1 prior to circumcision (the method for circumcision was sleeve resection using a ring device). Two doses, one of 30 U kg À1 before the procedure and a second dose of 30 U kg À1 on postoperative day 3, were given for major surgery. This strategy was also used for neurosurgery, but the dose was increased to 50 U kg À1 both before and after the operative procedures. Moreover, tranexamic acid and a local hemostatic agent were also used after circumcision, tooth extraction and Cesarean section for 5-7 days. was given every 2 weeks during pregnancy, and tranexamic acid was given during and after delivery, leading to successful delivery with no detectable abortion ( Table 1) . All of the patients tolerated surgery and experienced no bleeding events or non-hemostatic complications, except for two patients who had bleeding events; one was undiagnosed post-circumcision, and the second bled from the suture site on post hysterectomy day 6. Both had a good response to one additional dose of replacement therapy, 30 U kg À1 and 20 U kg À1 , respectively. Moreover, three non-hemostatic thrombotic complications were recorded. One patient was overweight (body mass index was 26.5) and developed localized lower extremity deep vein thrombosis (DVT) on post-Cesarean section day 3. She did recover after treatment with 14 days of anticoagulation (Enoxaparin) therapy with no need for longer treatment. The second patient developed right lower extremity DVT post-orthopedic surgery immediately after a leg fracture and prolonged immobilization. He was diagnosed after this surgery so that his DVT was not related to replacement therapy. He had had no life-threatening symptoms prior to current surgery; therefore, the definitive diagnosis of FXIII deficiency was postponed despite a positive history of skin bruising and umbilical cord and gum bleeding. The third patient was diagnosed at the age of 11 but refused to take prophylaxis, and she developed a huge lumbosacral hematoma following a fall at age 16, causing her to become paraplegic. She developed extensive bed sores on her back and underwent skin grafts twice and surgeries to evacuate a thigh hematoma, but she developed iliofemoral vein thrombosis after the third surgery on postoperative day 4 ( Table 1) . She underwent 2 weeks of low-molecular-weight heparin (Enoxaparin) administration at a dose of 1 mg kg À1 every 12 h subcutaneously, followed by oral anticoagulation (warfarin) for 6 months because of extensive thrombosis. The patient received anticoagulation and FXIII prophylaxis (10 U kg À1 ) simultaneously. All thrombophilia tests were negative for these three patients. Therefore, the actual rate of postoperative complications is 1.8%.
Patients who underwent obstetrical and gynecological surgeries (median age, 29 years) were older than those who underwent major (median age, 14 [0.17-38] years) and minor (median, 9 [0.4-37] years) surgeries. The median factor activity level was 0.6% (0.1-1.4%) in obstetrical and gynecological surgeries, 1.1% (0.1-1.5%) in major surgeries and 1.2% (0.1-4.5%) in minor surgeries. Postoperative complications occurred in one (1.8%) of the patients who underwent minor surgeries, in two (2.5%) of those who underwent major surgeries and in two (8%) of those who underwent obstetrical and gynecological surgeries.
All the patients had negative viral hepatitis markers (hepatitis B, C and HIV) at postoperative months 3 and 6. Eleven patients had surgeries based on a qualitative test, but all had good outcomes except one patient who underwent hysterectomy and had postoperative oozing from the site of suture on day 6. She did not receive a second dose on postoperative day 3 and was referred to our hemophilia center after being discharged from the hospital on postoperative day 6 when she was given a single dose of 20 U kg À1 , and subsequently showed a good response with no bleeding event.
Mutation analysis was performed in almost all cases. The results were mainly the Try187Arg variant, which included 51 cases of minor surgeries (circumcision is considered a minor surgery) and 100 cases of major surgeries. All of these patients were from southeast Iran, but two patients with major surgeries had the mutations Arg77His and Arg506Gln; these patients were from southern Iran. The results of genetic analysis were not available for nine patients.
Discussion
The lack of accepted standardized surgical guidelines causes dependence on the treating physicians' and centers' experiences [14, 15] . With this variable, a treatment protocol has been designed based on our experience. A single dose of 10 U kg À1 for minor surgery and 30 U kg À1 for circumcision or major surgery were given and are expected to increase FXIII levels to 25% and 75%, respectively. FXIII activity levels can be above 100% for neurosurgery after giving 50 U kg À1 . We have not performed a pharmacokinetic (PK) study on our patients, but published pharmacokinetic studies of FXIIID have shown a minimum plasma concentration of 0.9 AE 0.2 U mL À1 (mean AE SD, equivalent to 90 AE 20%) and a half-life of 6.6 AE 2.29 days (mean AE SD) after giving a dose of 40 U kg
À1
. Moreover, 40 U kg À1 every 28 days maintains trough FXIII activity > 10% [14, 16] . The results of our surgical outcomes appeared to be excellent hemostatic coverage with little postoperative bleeding, which showed that the designed dosage regimens of FXIII concentrate are consistent with the reported FXIII PK studies. Circumcision is apparently a minor surgery, but exposed mucosa and traumatic-contact skin mucosa are common causes of post-circumcision re-bleeding; as such, we preferred the minimum target level higher than 50%, as for major surgery [17] . Although EN-RBD data recorded bleeding events in FXIIID patients at levels of 5-30% [18] , a FXIII activity level of 15% was reported to be a reasonable suggested cut-off point to prevent spontaneous major bleeding [19] . Some studies proposed that a dose of 10-20 U kg À1 and a minimum target level of 5% would be safe for surgery, but some recommended the minimum level of 10-20% [20, 21] . Some authors suggested that a single dose of 20-30 U kg À1 may be uneventful for surgical procedures, although others recommended continuing with 10-20 U kg À1 per day for 2-3 days post-surgery, aiming to keep the level above 5% during surgery [21] [22] [23] . It seems that the goal would be to maintain the levels above 30% and 50% during delivery and major surgeries, respectively [24] . Previous reported data suggested a total variable dose of 250-1000 units given preoperatively for minor surgery [9, 25, 26] , which cannot be accurate because of variety in age and weight. A study on six FXIIID patients undergoing four major and two minor surgeries showed that maintaining levels above 50% is more advisable in order to have excellent hemostasis, although higher levels of 100% or more should be taken into consideration for complicated or prolonged surgeries [14, 27] . In our study, the most common type of minor surgery was tooth extraction, and a single dose of 10 U kg À1 along with adjuvant concomitant use of tranexamic acid resulted in a good hemostatic coverage. Moreover, based on the wide variation of FXIII half-life, we scheduled patients to receive a second dose of 30 U kg À1 and 50 U kg À1 for major and cranial surgeries, respectively, on postoperative day 3 in order to maintain a safe FXIII level and to expedite the wound healing process. In our study, two patients had a postoperative hemostatic complication; one had a lack of hemostatic coverage because of a missing diagnosis and the second patient had posthysterectomy bleeding from the site of suture on postoperative day 6, which may have been because of delayed administration of the second dose. The bleeding was stopped after giving an additional single dose of 20 U kg À1 and there were no subsequent bleeding episodes.
Three patients had postoperative DVT, and one of these events was not related to factor replacement. The other two cases were accompanied by risk factors other than factor replacement, such as being overweight and having a Cesarean section in one patient and being bedridden as a result of paraplegia in another case, all factors predisposing to thrombosis.
In FXIIID patients, the availability of both recombinant and plasma-derived FXIII concentrate makes performing surgery more feasible, resulting in a reduced bleeding risk and improved quality of life [22] . Our study showed minimal postoperative complications (1.8%). Additionally, none of the patients developed viral hepatitis, confirming the efficacy and safety of the plasmaderived FXIII concentrate.
A limitation of our study was unmeasured post-surgery FXIII activity and lack of a PK study, so that the minimum postoperative trough levels were not determined. The strong point was that we investigated a large number of patients, including all FXIIID patients registered in the two centers who have undergone surgery. This creates a high level of generalizability of the study results.
In conclusion, our study showed excellent hemostasis in FXIIID patients undergoing surgeries. A single preoperative dose for minor surgery and two doses of FXIII concentrate pre-and postoperatively after major and cranial surgeries seem to be sufficient in patients already on regular prophylaxis, resulting in excellent hemostasis. *All cases were a result of intracranial hemorrhage, nine spontaneous and two after a car accident, and VP shunt insertion was performed for nine of them. †One of the patients with thigh hematoma evacuation had also endured skin graft surgeries twice, which is not included in the table. This patient also experienced complications of postoperative iliofemoral thrombosis. ‡Tranexamic acid and a local hemostatic agent were also used after circumcision, tooth extraction and Cesarean section for 5-7 days.
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